FDA’s Prasad Exits After Sarepta Gene Therapy Controversy

Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his handling of Sarepta Therapeutics Inc.’s gene therapy.

Lue alkuperäinen artikkeli

Lisätietoja Toimitus

Toimitus

Katso myös

US to Ease Ship Rule in Bid to Tame Spiraling Fuel Prices

The Trump administration plans to waive a century-old maritime law that requires American ships be …